2月25日，博雅生物涨0.59%，成交额7261.74万元。两融数据显示，当日博雅生物获融资买入额1233.54 万元，融资偿还972.60万元，融资净买入260.94万元。截至2月25日，博雅生物融资融券余额合计6.86亿 元。 机构持仓方面，截止2025年9月30日，博雅生物十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股888.43万股，相比上期减少1815.54万股。招商国证生物医药指数A（161726）位居第六大 流通股东，持股434.18万股，相比上期减少75.06万股。 融资方面，博雅生物当日融资买入1233.54万元。当前融资余额6.83亿元，占流通市值的6.07%，融资余 额超过近一年80%分位水平，处于高位。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 融券方面，博雅生物2月25日融券偿还1900.00股，融券卖出4000.00股，按当日收盘价计算，卖出金额 8.92万元；融券余量12.23万股， ...

Core Viewpoint - The financial performance and trading activity of Boya Bio-Pharmaceutical Co., Ltd. indicate a mixed outlook, with a notable increase in revenue but a decline in net profit, alongside significant trading volumes in both margin financing and securities lending [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Boya Bio achieved a revenue of 1.474 billion yuan, representing a year-on-year growth of 18.38% [2]. - The net profit attributable to shareholders for the same period was 343 million yuan, which reflects a year-on-year decrease of 16.90% [2]. - Cumulatively, the company has distributed a total of 1.007 billion yuan in dividends since its A-share listing, with 489 million yuan distributed over the past three years [3]. Group 2: Trading Activity - On January 30, Boya Bio's stock price decreased by 0.86%, with a trading volume of 137 million yuan [1]. - The margin financing data for January 30 shows a buying amount of 17.01 million yuan and a repayment of 18.94 million yuan, resulting in a net margin buy of -1.93 million yuan [1]. - The total margin financing and securities lending balance as of January 30 was 684 million yuan, with the margin balance accounting for 5.89% of the circulating market value, indicating a high level compared to the past year [1].

Group 1 - The core viewpoint of the news is that Boya Bio's stock performance and financing activities indicate a mixed outlook, with significant financing activity but a decline in net profit year-over-year [1][2]. - On January 9, Boya Bio's stock rose by 0.82%, with a trading volume of 110 million yuan. The financing buy-in amount was 17.34 million yuan, while the financing repayment was 35.24 million yuan, resulting in a net financing outflow of 17.89 million yuan [1]. - As of January 9, the total balance of margin trading for Boya Bio was 685 million yuan, with a financing balance of 683 million yuan, accounting for 5.76% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - As of December 31, Boya Bio had 30,100 shareholders, a slight decrease of 0.03% from the previous period, while the average circulating shares per person increased by 0.03% to 16,737 shares [2]. - For the period from January to September 2025, Boya Bio reported a revenue of 1.474 billion yuan, representing a year-over-year growth of 18.38%. However, the net profit attributable to the parent company was 343 million yuan, reflecting a year-over-year decrease of 16.90% [2]. - Boya Bio has distributed a total of 1.007 billion yuan in dividends since its A-share listing, with 489 million yuan distributed over the past three years [3].

Core Insights - On October 15, Boya Bio's stock increased by 0.08%, with a trading volume of 63.16 million yuan [1] - The company reported a financing net purchase of 2.14 million yuan on the same day, with a total financing balance of 671 million yuan [1][2] - Boya Bio's main business revenue composition includes 84.58% from blood products, 8.63% from biochemical drugs, and 6.12% from distribution [1] Financing and Trading Activity - On October 15, Boya Bio had a financing buy amount of 10.86 million yuan and a financing repayment of 8.72 million yuan, resulting in a net financing purchase of 2.14 million yuan [1] - The current financing balance of 669 million yuan accounts for 5.35% of the circulating market value, indicating a high level compared to the past year [1] - The company had a securities lending balance of 2.34 million yuan, with a lending volume of 94,400 shares, also reflecting a high level compared to the past year [1] Shareholder and Financial Performance - As of September 30, Boya Bio had 30,200 shareholders, an increase of 0.32% from the previous period, with an average of 16,694 circulating shares per person, a decrease of 0.32% [2] - For the first half of 2025, Boya Bio achieved an operating income of 1.008 billion yuan, a year-on-year increase of 12.51%, while the net profit attributable to shareholders decreased by 28.68% to 225 million yuan [2] - The company has distributed a total of 1.007 billion yuan in dividends since its A-share listing, with 489 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 27.04 million shares, a decrease of 800,100 shares from the previous period [3] - The sixth-largest circulating shareholder, China Merchants Guozhen Biomedicine Index A, held 5.09 million shares, down by 512,100 shares [3] - Notably, the E Fund Growth Enterprise Board ETF and GF Healthcare Stocks A have exited the top ten circulating shareholders list [3]